| Code | CSB-RA723415MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody JAB-BX102, targeting NT5E (ecto-5'-nucleotidase, also known as CD73). NT5E is an ectoenzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E contributes to immunosuppression through adenosine receptor activation on immune cells, thereby inhibiting T cell and NK cell functions. Elevated NT5E expression is associated with poor prognosis in various cancers, including triple-negative breast cancer, melanoma, and ovarian cancer, making it an important target in immuno-oncology research.
As a biosimilar to JAB-BX102, this antibody provides researchers with a reliable tool for investigating NT5E-mediated immune evasion mechanisms and evaluating therapeutic strategies targeting the adenosine pathway. It supports studies examining tumor immunology, cancer metabolism, and the development of combination immunotherapy approaches. This antibody enables detailed characterization of NT5E expression patterns and functional consequences in various experimental models.
There are currently no reviews for this product.